ALLE for en

William Blair analyst R. Merkel now forecasts that the scientific and technical instruments company will earn $1.44 per share for the quarter, down from their ...

The stock was sold at an average price of $114.02, for a total value of $249,247.72. Following the completion of the sale, the senior vice president now owns 12,988 shares of the company’s stock, valued at $1,480,891.76. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Intercontinental Wealth Advisors LLC now owns 3,779 shares of the scientific and technical instruments company’s stock valued at $500,000 after acquiring an additional 1,651 shares during the period. The shares were sold at an average price of $114.02, for a total transaction of $249,247.72. Following the transaction, the senior vice president now owns 12,988 shares of the company’s stock, valued at $1,480,891.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The stock was sold at an average price of $112.07, for a total value of $240,950.50. Following the transaction, the senior vice president now owns 5,433 shares in the company, valued at $608,876.31. The disclosure for this sale can be found here. Canada Pension Plan Investment Board now owns 31,600 shares of the scientific and technical instruments company’s stock worth $4,185,000 after buying an additional 30,795 shares during the period. Van ECK Associates Corp now owns 10,862 shares of the scientific and technical instruments company’s stock valued at $1,439,000 after acquiring an additional 1,234 shares during the last quarter. Ensign Peak Advisors Inc now owns 42,709 shares of the scientific and technical instruments company’s stock worth $5,656,000 after purchasing an additional 8,966 shares during the period. TD Asset Management Inc. now owns 57,572 shares of the scientific and technical instruments company’s stock worth $7,625,000 after buying an additional 4,092 shares during the last quarter. Morgan Stanley lifted their price target on Allegion from $115.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Friday. Wells Fargo & Company lowered their price objective on shares of Allegion from $118.00 to $115.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 12th. The scientific and technical instruments company reported $1.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.04. The business had revenue of $773.10 million during the quarter, compared to the consensus estimate of $771.68 million. Robert W. Baird cut their target price on shares of Allegion from $120.00 to $116.00 and set a “neutral” rating for the company in a research report on Monday, July 18th. Finally, The Goldman Sachs Group reduced their price target on shares of Allegion from $140.00 to $113.00 and set a “buy” rating on the stock in a report on Thursday, June 23rd.